scholarly journals CTGF is a therapeutic target for metastatic melanoma

Oncogene ◽  
2013 ◽  
Vol 33 (9) ◽  
pp. 1093-1100 ◽  
Author(s):  
E C Finger ◽  
C-F Cheng ◽  
T R Williams ◽  
E B Rankin ◽  
B Bedogni ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Therapeutic Target

scholarly journals Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma

2017 ◽  
Vol 110 (3) ◽  
pp. 290-303 ◽  
Author(s):  
Valentina Audrito ◽  
Antonella Managò ◽  
Sofia La Vecchia ◽  
Federica Zamporlini ◽  
Nicoletta Vitale ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Therapeutic Target ◽  
Nicotinamide Phosphoribosyltransferase

scholarly journals Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Runhua Feng ◽  
Yuling Wang ◽  
Vijaya Ramachandran ◽  
Qinhong Ma ◽  
Matthew M. May ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Metastatic Melanoma ◽  
Therapeutic Target ◽  
High Throughput Screening ◽  
Conformational Epitope ◽  
Migration And Invasion ◽  
Melanoma Tumor ◽  
Downstream Signaling

Abstract Background MUC18 is a glycoprotein highly expressed on the surface of melanoma and other cancers which promotes tumor progression and metastasis. However, its mechanism of action and suitability as a therapeutic target are unknown. Methods A monoclonal antibody (mAb) (JM1-24-3) was generated from metastatic melanoma tumor live cell immunization, and high-throughput screening identified MUC18 as the target. Results Analysis of molecular interactions between MUC18 and JM1-24-3 revealed that the downstream signaling events depended on binding of the mAb to a conformational epitope on the extracellular domain of MUC18. JM1-24-3 inhibited melanoma cell proliferation, migration and invasion in vitro and reduced tumor growth and metastasis in vivo. Conclusion These results confirm that MUC18 is mechanistically important in melanoma growth and metastasis, suggest that the MUC18 epitope identified is a promising therapeutic target, and that the JM1-24-3 mAb may serve as the basis for a potential therapeutic agent.

scholarly journals KIT as a Therapeutic Target in Metastatic Melanoma

JAMA ◽  
2011 ◽  
Vol 305 (22) ◽  
pp. 2327 ◽  
Author(s):  
Richard D. Carvajal
Keyword(s):  
Metastatic Melanoma ◽  
Therapeutic Target

1027 CD133 (Prominin-1) as a Therapeutic Target in Metastatic Melanoma

2012 ◽  
Vol 48 ◽  
pp. S248
Author(s):  
G. Rappa ◽  
J. Mercapide ◽  
F. Anzanello ◽  
A. Lorico
Keyword(s):  
Metastatic Melanoma ◽  
Therapeutic Target

Memapsin 2, a drug target for Alzheimer's disease

2003 ◽  
Vol 70 ◽  
pp. 213-220 ◽  
Author(s):  
Gerald Koelsch ◽  
Robert T. Turner ◽  
Lin Hong ◽  
Arun K. Ghosh ◽  
Jordan Tang
Keyword(s):  
Crystal Structure ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Transition State ◽  
Amyloid Precursor Protein ◽  
Therapeutic Target ◽  
Drug Target ◽  
Aspartic Protease ◽  
Precursor Protein ◽  
Memapsin 2

Mempasin 2, a ϐ-secretase, is the membrane-anchored aspartic protease that initiates the cleavage of amyloid precursor protein leading to the production of ϐ-amyloid and the onset of Alzheimer's disease. Thus memapsin 2 is a major therapeutic target for the development of inhibitor drugs for the disease. Many biochemical tools, such as the specificity and crystal structure, have been established and have led to the design of potent and relatively small transition-state inhibitors. Although developing a clinically viable mempasin 2 inhibitor remains challenging, progress to date renders hope that memapsin 2 inhibitors may ultimately be useful for therapeutic reduction of ϐ-amyloid.

Sign in / Sign up

Export Citation Format

Share Document